Advanced inoperable type B3 thymoma: Monitoring of a novel therapeutic approach with radio-chemo therapy and sorafenib by FDG-PET and CT

• References

• 1 Antoch G, Kanja J, Bauer S. et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004; 45: 357-365.
• 2 Blumberg D, Burt ME, Bains MS. et al. Thymic carcinoma: current staging does not predict prognosis. J Thorac Cardiovasc Surg 1998; 115: 303-309.
• 3 Detterbeck FC, Parsons AM. Thymic tumors. Ann Thorac Surg 2004; 77: 1860-1869.
• 4 Endo M, Nakagawa K, Ohde Y. et al. Utility of ¹⁸FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors. Lung Cancer 2008; 61: 350-355.
• 5 Fornasiero A, Daniele O, Ghiotto C. et al. Chemotherapy of invasive thymoma. J Clin Oncol 1990; 8: 1419-1423.
• 6 Greene MA, Malias MA. Aggressive multimodality treatment of invasive thymic carcinoma. J Thorac Cardiovasc Surg 2003; 125: 434-436.
• 7 Hejna M, Haberl I, Raderer M. et al. Nonsurgical management of malignant thymoma. Cancer 1999; 85: 1871-1884.
• 8 Jeong YJ, Lee KS, Kim J. et al. Does CT of thymic epithelial tumors enable us to differentiate histologic subtypes and predict prognosis?. AJR Am J Roentgenol 2004; 183: 283-289.
• 9 Khosravi Shahi P, Fernandez Pineda I. Tumoral angiogenesis: review of the literature. Cancer Invest 2008; 26: 104-108.
• 10 Masaoka A, Monden Y, Nakahara K. et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981; 48: 2485-2492.
• 11 Molhoek KR, Griesemann H, Shu J. et al. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res 2008; 68: 4392-4397.
• 12 Ogawa K, Toita T, Uno T. et al. Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. Cancer 2002; 94: 3115-3119.
• 13 Prior JO, Montemurro M, Orcurto MV. et al. Early prediction of response to sunitinib after imatinib failure by ¹⁸F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 2009; 27: 439-445.
• 14 Rea F, Marulli G, Girardi R. et al. Long-term survival and prognostic factors in thymic epithelial tumours. Eur J Cardiothorac Surg 2004; 26: 412-418.
• 15 Sadohara J, Fujimoto K, Muller NL. et al. Thymic epithelial tumors: comparison of CT and MR imaging findings of low-risk thymomas, high-risk thymomas, and thymic carcinomas. Eur J Radiol 2006; 60: 70-79.
• 16 Stroobants S, Goeminne J, Seegers M. et al. ¹⁸FDG- Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 39: 2012-2020.
• 17 Sung YM, Lee KS, Kim BT. et al. ¹⁸F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups. J Nucl Med 2006; 47: 1628-1634.
• 18 Tomita M, Matsuzaki Y, Edagawa M. et al. Correlation between tumor angiogenesis and invasive- ness in thymic epithelial tumors. J Thorac Cardio- vasc Surg 2003; 124: 493-498.
• 19 Travis WD, Muller-Hermelink HK, Harris CC. Pathology and genetics of tumours of the lung, pleura, thymus and heart. WHO classification of tumours. IARC Press 2004; 145-197.
• 20 Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002; 38 Suppl 5 S60-S65.
• 21 Wilhelm SM, Adnane L, Newell P. et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor ty- rosine kinase signaling. Mol Cancer Ther 2008; 7: 3129-3140.
• 22 Wilhelm SM, Carter C, Tang L. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.